Fig. 5.
The effects of anti-Fas ligand antibody administration in vivo and the transfer of Fas ligand defective B6 spleen cells. The mice were received 500 μg/body of MoAb against Fas ligand on days 0, 1, 4, 7, and 10 after B6 spleen cell transfer (B6/BDF1 αFas-L). The mice were injected with 5 × 107 of FasL-defective (gld) B6 spleen cells (gld/BDF1) or B6 cells (B6/BDF1). On day 14 after transfer, the mice were killed to remove their BM cells. The total cell numbers from five mice were expressed as the mean ± SEM. BDF1 represents the control mice injected with the same amounts of rat IgG1 intraperitoneally on the same schedule as mentioned above. *Significant increase versus B6/BDF1 (P < .01).
